BioInvent KOL Call on Relapsed or Refractory Non-Hodgkin’s Lymphoma – $116M Raise

140 overall attendees, including institutional investors, sell-side analysts, bankers, high net worth investors, and strategics

With our proprietary distribution network, LifeSci hosted a total of 140 overall attendees, including institutional investors, sell-side analysts, bankers, high net worth investors, and strategics

 

What: KOL Call on BI-1206 for Relapsed or Refractory Non-Hodgkin’s Lymphoma
When: January 28, 2021
Who: Dr. Martin Welschof, CEO
Dr. Andres McAllister, CMO
Dr. Björn Frendéus, CSO
Dr. Mats Jerkeman (Lund University)
Wei-Wu He, Casi Chairman and CEO
Weihao Xu, Casi CFO
Why: Clinical update on BI-1206 for Relapsed or Refractory Non-Hodgkin’s Lymphoma
Format: Speakers’ presentations followed by live Q&A
Outcome: 140 live participants on the call High quality institutional and retail investors
11 sell-side analysts, 7 from the US 74 minutes in duration 20 questions received live via Q&A Function